ANGO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ANGO looks like a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock has a bullish technical setup, supportive analyst sentiment, and a meaningful event-driven catalyst from Medicare coverage expansion for NanoKnife. While there is no proprietary AI Stock Picker or SwingMax signal today, the current setup still favors a direct buy rather than waiting for a perfect entry, especially given the long-term growth angle.
ANGO's current price is 11.89, slightly above the previous close of 11.79. Trend signals are constructive: MACD histogram is positive at 0.0708, moving averages are bullish with SMA_5 > SMA_20 > SMA_200, and RSI_6 at 65.051 is elevated but not overbought enough to negate the trend. Key levels show nearby resistance at 12.056 and 12.422, with support at 10.872 and 10.506. Overall, the chart suggests an uptrend with moderate near-term momentum and room to continue higher.
["Palmetto GBA issued a final Local Coverage Determination effective July 5, 2026, giving Medicare coverage for irreversible electroporation used in AngioDynamics' NanoKnife system for prostate and liver cancers.", "The AMA activated Category I CPT codes for IRE procedures, improving billing standardization and supporting adoption.", "Freedom Broker initiated coverage with a Buy rating and $16 target, citing an improved growth profile from the company's move toward higher-growth medical technology platforms.", "Canaccord maintained a Buy rating and $16 target after a solid FQ3 revenue beat and raised guidance for revenue, adjusted EBITDA, and adjusted EPS."]
["Canaccord reduced its target from $18 to $16, suggesting some valuation moderation even while remaining bullish.", "The stock showed only a modest reaction near term, and the technical trend is positive but not strongly explosive.", "Hedge funds and insiders are neutral, so there is no strong accumulation signal from those groups.", "No recent congress trading data or influential figure transactions were reported."]
Latest quarter information was not fully provided in the financial snapshot, but analyst commentary indicates FQ3 was strong: revenue beat expectations and the company raised revenue, adjusted EBITDA, and adjusted EPS guidance while keeping gross margin guidance unchanged. For a growth-oriented medical technology company, that points to improving operating momentum in the latest reported quarter, which is supportive for a long-term thesis.
Recent analyst trend is positive. Freedom Broker initiated Buy coverage with a $16 target, and Canaccord also kept a Buy rating while lowering its target to $16 from $18 after a good FQ3. The Wall Street pros view is constructive overall: they see better growth prospects and stronger fundamentals. The cons view is that the target cut and comments about EBITDA optics suggest some skepticism about the pace or quality of near-term earnings expansion.
